Translator Disclaimer
1 August 2013 Development of the S3Pvac Vaccine Against Murine Taenia crassiceps Cysticercosis: A Historical Review
Author Affiliations +
Abstract
Our work of the last 25 yr was concerned with the development of a vaccine aimed to prevent porcine Taenia solium cysticercosis and was based on cross-reacting Taenia crassiceps antigens that had proved protective against experimental intraperitoneal murine T. crassiceps cysticercosis (EIMTcC). In recent times the efficacy of the vaccine has been considered in need of confirmation, and the use of EIMTcC has been questioned as a valid tool in screening for vaccine candidates among the many antigens possibly involved. A review of our work divided in 2 parts is presented at this point, the first dealing with EIMTcC and the second with porcine T. solium cysticercosis (presented in this issue). Herein, we revise our results using EIMTcC as a measure of the protective capacity of T. crassiceps complex antigen mixtures, of purified native antigens, and of S3Pvac anti-cysticercosis vaccine composed by 3 protective peptides: GK-1, KETc1, and KETc12 either synthetic or recombinantly expressed and collectively or separately, by diverse delivery systems when administered at different doses and by different routes. Statistical analyses of the data lead confidently to the strong inference that S3Pvac is indeed an effective vaccine against EIMTcC via specific and non-specific mechanisms of protection.
Edda Sciutto, Gladis Fragoso, Marisela Hernández, Gabriela Rosas, José J. Martínez, Agnès Fleury, Jacquelynne Cervantes, Aline Aluja and Carlos Larralde "Development of the S3Pvac Vaccine Against Murine Taenia crassiceps Cysticercosis: A Historical Review," Journal of Parasitology 99(4), (1 August 2013). https://doi.org/10.1645/GE-3101.1
Received: 27 January 2012; Accepted: 1 February 2013; Published: 1 August 2013
JOURNAL ARTICLE
10 PAGES


SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top